FoRx Therapeutics raises Eur 10M seed-financing round: the advisor

FoRx Therapeutics, a Basel-based biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways activated in cancer, completes a EUR 10M seed-financing round led by M Ventures (venture capital arm of Merck), Novartis Venture Fund and Omega Funds. Pfizer Ventures, the venture capital arm of Pfizer and Life Sciences Partners also joined the seed-financing. In this context, FoRx is developing a new generation of drugs against a unique target class for the treatment of cancer.

The team

VISCHER advises FoRx Therapeutics on all Swiss legal issues in this transaction. The team includes partner Christian Wyss (life sciences – pictured), associates Dania Salvisberg-Schneider, Luzius Zumstein (both corporate and m&a), Fiona Gao (life sciences), Beatrice Leistner (tax), and Gian Geel (employment).